+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Autologous activated macrophages (MAK) coated ex vivo with humanized anti-CD20 monoclonal antibodies can eradicate minimal residual disease in chronic lymphocytic leukaemia in clinical response



Autologous activated macrophages (MAK) coated ex vivo with humanized anti-CD20 monoclonal antibodies can eradicate minimal residual disease in chronic lymphocytic leukaemia in clinical response



British Journal of Haematology 142(6): 996-998




Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 051723836

Download citation: RISBibTeXText

PMID: 18665839

DOI: 10.1111/j.1365-2141.2008.07272.x


Related references

Treatment of severe chronic lymphocytic leukemia in residual disease stage with autologous macrophages activated and associated to humanized anti-CD20 antibodies. Blood 96(11 Part 2): 295b, 2000

Anti-CD20 monoclonal antibody-dependent phagocytosis of chronic lymphocytic leukaemia cells by autologous macrophages. Clinical and Experimental Immunology 183(1): 90, 2016

Rituximab, ofatumumab and other monoclonal anti-CD20 antibodies for chronic lymphocytic leukaemia. Cochrane Database of Systematic Reviews 11: Cd008079, 2012

CD43 and integrin beta7 expression in the assessment of mininal residual disease in chronic lymphocytic leukemia A potentially useful tool in patients receiving anti-CD20 monoclonal antibodies. Blood 102(11): 354b, 2003

Intravenous infusion of activated autologous macrophages armed with anti-CD20 monoclonal antibodies can yield sustained molecular remission in CLL. Blood 98(11 Part 1): 808a, 2001

Different clinical value of minimal residual disease after autologous and allogenic stem cell transplantation for chronic lymphocytic leukemia. Blood 99(5): 1873-1874, 2002

Anti-CD20 monoclonal antibodies in chronic lymphocytic leukemia. Expert Opinion on Biological Therapy 13(2): 169-182, 2013

The addition of CD20 monoclonal antibodies to lenalidomide improves response rates and survival in relapsed/refractory patients with chronic lymphocytic leukaemia relative to lenalidomide monotherapy - the MD Anderson Cancer Center experience. British Journal of Haematology 171(2): 281-284, 2015

Citrobacter koseri cellulitis during anti-CD20 monoclonal antibody (ofatumumab) treatment for B-cell chronic lymphocytic leukaemia. ActaDermato-Venereologica90(1):99, 2010

Minimal residual disease in chronic lymphocytic leukaemia. Medicina Clinica 150(4): 144-149, 2018

Post-remission intervention with alemtuzumab or rituximab to eradicate minimal residual disease in chronic lymphocytic leukemia: where do we stand?. Leukemia and Lymphoma 53(3): 362-370, 2012

Comparison of the in vitro effects of the anti-CD20 antibodies rituximab and GA101 on chronic lymphocytic leukaemia cells. British Journal of Haematology 152(3): 295-306, 2011

The latest developments with anti-CD20 monoclonal antibodies in chronic lymphocytic leukemia. Expert Opinion on Biological Therapy 18(9): 973-982, 2018

Anti-CD20 monoclonal antibodies in chronic lymphocytic leukemia: from uncertainties to promises. ImmunoTherapy 8(5): 569-581, 2016

Minimal residual disease assessment in chronic lymphocytic leukaemia. Best Practice and Research. Clinical Haematology 20(3): 499-512, 2007